Hackensack 385 Prospect Avenue Suite 101 Hackensack, NJ, 07601 **Princeton / Somerset** 49 Veronica Avenue Suite 202 Somerset, NJ 08873

Long Branch 422 Morris Avenue Suite 7 Long branch, NJ 07740 Marlton

127 Church Road

Suite 600

Marlton, NJ 08053

n Vewell T S 0 N Office: 212-803-3339 Fax: 646-768-8600



RIABNI® (rituximab-arrx)

ORDER FORM Date: _____

PATIENT INFORMATION				
Name:	Phone	:	DOB: SEX: M 🗆 F 🗆	
□NKDA Allergies:			Weight lbs/kg:	
PHYSICIAN INFORMATION				
Physician Name*: Practice Name:				
Address:		Office Contact Name:	Office Contact #:	
Phone: Fax:		Email (for updates):		
REFERRAL STATUS				
□New Referral □Referral Renewal □Med	ication/	Order Change 🛛 🗆 Benefits Ve	erification Only Discontinuation Order	
RIABNI: is indicated for the treatment of adult patients with:				
 Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 				
ICD-10*: Dx Code:		DOSING AND IN B-cell NHL is 375 mg/m2	DOSING AND INDICATION B-cell NHL is 375 mg/m2	
Dx Code:	 combination with FC, adn RA in combination with r separated by 2 weeks (one evaluation, but not soone intravenous or equivalent each infusion. For adult patients with act glucocorticoids is 375 mg The follow up dose for adh disease control with induc coids is two 500 mg intrav by a 500 mg intravenous i evaluation. 	 separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks. Methylprednisolone 100 mg intravenous or equivalent glucocorticoid is recommended 30 minutes prior to each infusion. For adult patients with active GPA and MPA in combination with glucocorticoids is 375 mg/m2 once weekly for 4 weeks. The follow up dose for adult patients with GPA and MPA who have achieved disease control with induction treatment, in combination with glucocorticoids is two 500 mg intravenous infusion separated by two weeks, followed by a 500 mg intravenous infusion every 6 months thereafter based on clinical evaluation. 		
	ion.		WARNINGS AND PRECAUTIONS https://www.pi.amgen.com/-/media/Project/Amgen/Repositorypi-amgen-com/Riabni/riabni_pi_english.pdf	
Injection: 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg solution in single-dose vials (3)	(10 mg/mL) and 500 mg/50 mL (10 mg/mL) Ils (3)		MENTATION CHECKLIST:	
FREQUENCY		Patient Demogra		
□ Date of last dose:			clude CBC w/diff + Plts, CMP, HBsAg and	
			, i i i i i i i i i i i i i i i i i i i	
			initiating treatment with RIABNI (rituximab-arr	
			any other recent labs	
		Ű	nd Vaccination Status	
		Other		
		(

ORDERING PROVIDER

Signature X _____ Date _____

_____ Phone _____ Fax _____

Provider